Literature DB >> 2536005

Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia.

L Dillner1, Z Bekassy, N Jonsson, J Moreno-Lopez, J Blomberg.   

Abstract

Although human papillomavirus (HPV) is involved in the etiology of cervical carcinoma, there are no cervical carcinoma-specific HPV serologic tests available. We investigated the presence of broadly cross-reactive IgA antibodies to papillomavirus (PV) in cervico-vaginal secretions from patients with condylomata and cervical intraepithelial neoplasia (CIN). Purified bovine PV (BPV) virions were used as antigen in an enzyme-linked immunosorbent assay (ELISA). Forty-two women whose ages ranged from 20 to 50 participated in the study. Eight of 9 patients with CIN had IgA antibodies against PV in their cervical secretions. Three of 9 patients with koilocytosis and condylomas but no CIN had IgA antibodies to PV. Six of 24 women with normal Pap-smear and colposcopy also had IgA antibodies against PV in their cervical secretions. The proportion of IgA-positive cervical secretions was significantly higher in the CIN group than in the normal group (p less than 0.005). Our data suggest that IgA antibodies to PV may be a useful marker for CIN.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536005     DOI: 10.1002/ijc.2910430109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Detection of human papillomavirus deoxyribonucleic acid in the female genital tract.

Authors:  J Czeglédy; L Gergely; Z Hernádi; R Póka
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

Review 2.  Local immunity and the uterine cervix: implications for cancer-associated viruses.

Authors:  J K Roche; C P Crum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia.

Authors:  J Dillner; L Dillner; J Robb; J Willems; I Jones; W Lancaster; R Smith; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses.

Authors:  L Dillner; P Heino; J Moreno-Lopez; J Dillner
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  Serological responses to papillomavirus group-specific antigens in women with neoplasia of the cervix uteri.

Authors:  L Dillner; J Moreno-Lopez; J Dillner
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

6.  Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.

Authors:  Z Wang; B G Hansson; O Forslund; L Dillner; M Sapp; J T Schiller; B Bjerre; J Dillner
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

Review 7.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

Review 8.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

10.  Seroreactivity to HPV-16 proteins in women with early cervical neoplasia.

Authors:  S R Barber; J Werdel; M Symbula; J Williams; B A Burkett; P T Taylor; J K Roche; C P Crum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.